10x Genomics, Inc.
TXG
株式のランク
#2195
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
株価
$72.61
時価総額
$9.46B
変化（1日）
3.88%
変化（1年）
452.55%
国
US
取引 10x Genomics, Inc. (TXG)
カテゴリー
Healthcare
10x Genomics, Inc.（TXG）のP/E比率
October 2026 時点のP/E比率 TTM -123.90
10x Genomics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -123.90 です。2023 年末時点での P/E は -25.70 でした。
10x Genomics, Inc. の P/E 比率の履歴（2017 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -123.90 | 1,208.32% |
| 2024 | -9.47 | -63.15% |
| 2023 | -25.70 | 2.83% |
| 2022 | -24.99 | -91.15% |
| 2021 | -282.32 | 969.76% |
| 2020 | -26.39 | -72.31% |
| 2019 | -95.31 | 1,417.64% |
| 2018 | -6.28 | -80.72% |
| 2017 | -32.58 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 19.68 | -115.88% |
US
|
|
| 64.40 | -151.98% |
AU
|
|
| 44.30 | -135.76% |
US
|
|
| -47.78 | -61.44% |
US
|
|
| - | - |
US
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。